High-intensity care for GDMT titration.
Jan BiegusMatteo PagnesiBeth DavisonPiotr PonikowskiAlexander MebazaaGadi CotterPublished in: Heart failure reviews (2024)
Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality, increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept of high-intensity care to optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights the importance of achieving optimal recommended doses of GDMT medications, including beta-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter inhibitors to improve patient outcomes, achieve effective, sustainable decongestion, and improve patient quality of life. The document also discusses potential obstacles to GDMT optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, and frailty. Lastly, it also attempts to provide possible future scenarios of high-intensive care that could improve patient outcomes.
Keyphrases
- high intensity
- healthcare
- heart failure
- resistance training
- angiotensin converting enzyme
- end stage renal disease
- palliative care
- angiotensin ii
- newly diagnosed
- quality improvement
- acute heart failure
- chronic kidney disease
- ejection fraction
- climate change
- prognostic factors
- human health
- stem cells
- peritoneal dialysis
- atrial fibrillation
- cardiovascular disease
- risk assessment
- adipose tissue
- risk factors
- coronary artery disease
- mesenchymal stem cells
- patient reported outcomes
- metabolic syndrome
- cell therapy
- body composition
- replacement therapy
- community dwelling